Vaccines to persistent parasite infections have been challenging, and current iterations lack
long-term protection. Cytomegalovirus (CMV) chronic vaccine vectors drive protection …

The development of a sterilizing vaccine against malaria remains one of the highest
priorities for global health research. While sporozoite vaccines targeting the pre-erythrocytic …

Latent cytomegalovirus (CMV) infection has widely reported immunomodulatory effects on
the immune system, leading to altered responses to vaccination or infection with other …

Following the RTS, S malaria vaccine, which showed only partial protection with short-term
memory, there is strong support to develop second-generation malaria vaccines that yield …

Despite recent advances in treatment and vector control, malaria is still a leading cause of
death, emphasizing the need for an effective vaccine. The malaria life cycle can be …

Protecting against both liver and blood stages of infection is a long-sought goal of malaria
vaccine design. Recently, we described the use of replication-defective viral vaccine vectors …

Vaccines have had a tremendous impact on the control of infectious diseases. Not only are
vaccines potentially the least expensive mechanism to combat infectious diseases, under …

Protection against liver-stage malaria relies on the induction of high frequencies of antigen-
specific CD8+ T cells. We have previously reported high protective levels against mouse …

A malaria vaccine strategy targeting multiple lifecycle stages may be required to achieve a
high level of efficacy. In two Phase IIa clinical trials, we tested immunogenicity and efficacy of …

Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver
stages and the disease-causing blood stages of the human malaria parasite Plasmodium …